ANTIBACTERIAL DRUGS MARKET ANALYSIS

One of the major challenges faced by the global antibacterial drugs market is growing antibiotic resistance. Increased antibiotic usage over the years has led to the development of drug-resistant microbial strains. Several common bacterial pathogens, such as Staphylococcus aureus, Streptococcus pneumoniae, and Escherichia coli, have now developed resistance to older classes of antibiotics. This has reduced the effectiveness of these drugs in treating infections caused by such antibiotic-resistant bacteria. Furthermore, development of multidrug-resistant bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA) poses serious treatment challenges. Limited pipeline of new antibiotics also aggravates the problem as there are no new drugs to replace older antibiotics rendered ineffective by resistance.

Antibacterial Drugs Market Opportunity - Development of novel antibiotics

One of the significant opportunities available for the global antibacterial drugs market is the development of novel antibiotics. The market is in urgent need of new antibiotics with novel mechanisms of action to combat the problem of growing antibiotic resistance. Several pharmaceutical companies and research institutes are involved in intensive research and clinical development of new classes of antibiotics with activity against multi-drug resistant bacteria. Some of the promising new candidates in clinical trials include novel antibiotics targeting bacterial cell wall synthesis, protein synthesis inhibition, DNA replication inhibition and cell membrane disruption. Regulatory agencies also encourage development of such first-in-class novel antibiotics through various incentives. Successful approval and launch of these new drug entities can revitalize the market by providing physicians effective treatment options for drug-resistant infections.